Central Trust Company’s BridgeBio Pharma BBIO Stock Holding History

Central Trust Company’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$149	–	1583
2026 Q1	$149	Hold	2	–	–	﹤0.01%	1550
2025 Q4	$153	Buy	+2	New	+$131	﹤0.01%	1514
2022 Q1	–	Sell	-100	Closed	-$2K	–	1347
2021 Q4	$2K	Hold	100	–	–	﹤0.01%	1195
2021 Q3	$5K	Hold	100	–	–	﹤0.01%	1114
2021 Q2	$6K	Buy	+100	New	+$5.71K	﹤0.01%	1071

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Central Trust Company's BBIO Position: Q2 2026 in Review

Central Trust Company sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 2 shares — an estimated $149 sold.

Central Trust Company first reported a position in BBIO in Q2 2021 and held it in 5 quarters. The position peaked at $6K in Q2 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Central Trust Company reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Central Trust Company sold 2 BridgeBio Pharma shares in Q2 2026, an estimated $149.
Central Trust Company first reported a position in BridgeBio Pharma in Q2 2021 and held it in 5 quarters.
Central Trust Company's BridgeBio Pharma position peaked at $6K in Q2 2021.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.